CDH2

Across TCGA pan-cancer cohorts, CDH2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDH2 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CDH2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CDH2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

UCEC, PDAC, and LUAD are the cancer types where CDH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	0.902	1.000	.006	42	view →
PDAC	DFS	Median	II,III,IV	0.300	0.674	<.001	31	view →
LUAD	OS	Tertile	III,IV	0.560	1.000	.027	14	view →
GBM	OS	Quartile	All	0.577	0.295	.021	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDH2–UCEC (OS)

Open the UCEC breakdown →